Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $60.8 million.

  • Innate Pharma's Cash & Equivalents fell 1934.5% to $60.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $60.8 million, marking a year-over-year decrease of 1934.5%. This contributed to the annual value of $71.9 million for FY2024, which is 590.74% down from last year.
  • According to the latest figures from Q2 2025, Innate Pharma's Cash & Equivalents is $60.8 million, which was down 1934.5% from $71.0 million recorded in Q4 2024.
  • Innate Pharma's Cash & Equivalents' 5-year high stood at $125.2 million during Q2 2021, with a 5-year trough of $60.8 million in Q2 2025.
  • Its 5-year average for Cash & Equivalents is $88.9 million, with a median of $77.8 million in 2023.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 9990.48% in 2021, then crashed by 307.73% in 2024.
  • Over the past 5 years, Innate Pharma's Cash & Equivalents (Quarter) stood at $118.7 million in 2021, then fell by 27.6% to $85.9 million in 2022, then dropped by 11.59% to $76.0 million in 2023, then decreased by 6.6% to $71.0 million in 2024, then dropped by 14.32% to $60.8 million in 2025.
  • Its Cash & Equivalents was $60.8 million in Q2 2025, compared to $71.0 million in Q4 2024 and $75.4 million in Q2 2024.